6.83

0.15% -0.010

Xeris Biopharma Holdings Inc (XERS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$6.84

Offen:

$6.82

24-Stunden-Volumen:

1.72M

Relative Volume:

0.73

Marktkapitalisierung:

$1.13B

Einnahmen:

$246.03M

Nettoeinkommen (Verlust:

$-32.00M

KGV:

-32.14

EPS:

-0.2125

Netto-Cashflow:

$-16.78M

1W Leistung:

-4.87%

1M Leistung:

-24.78%

6M Leistung:

+38.82%

1J Leistung:

+124.67%

1-Tages-Spanne:

$6.71

$6.935

1-Wochen-Bereich:

$6.71

$7.4979

52-Wochen-Spanne:

$3.02

$10.08

Xeris Biopharma Holdings Inc Stock (XERS) Company Profile

Firmenname

Xeris Biopharma Holdings Inc

Sektor

Healthcare (1129)

Branche

Biotechnology (632)

Telefon

844-445-5704

Adresse

1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL

Mitarbeiter

394

Twitter

@XerisPharma

Nächster Verdiensttermin

2024-12-08

Neueste SEC-Einreichungen

XERS's Discussions on Twitter

Vergleichen Sie XERS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
XERS Xeris Biopharma Holdings Inc	6.83	1.13B	246.03M	-32.00M	-16.78M	-0.2125
VRTX Vertex Pharmaceuticals Inc	426.76	107.15B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	755.90	77.46B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	436.38	58.90B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	918.92	56.55B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	198.76	42.58B	447.02M	-1.18B	-906.14M	-6.1812

Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-08-12	Fortgesetzt	H.C. Wainwright	Buy
2024-11-11	Herabstufung	Piper Sandler	Overweight → Neutral
2024-03-28	Eingeleitet	Oppenheimer	Outperform
2023-08-28	Eingeleitet	Craig Hallum	Buy
2022-10-21	Eingeleitet	Jefferies	Buy
2022-04-28	Eingeleitet	Craig Hallum	Buy
2021-11-17	Eingeleitet	SVB Leerink	Outperform
2021-10-29	Eingeleitet	H.C. Wainwright	Buy
2021-04-07	Fortgesetzt	RBC Capital Mkts	Outperform
2020-02-18	Eingeleitet	Piper Sandler	Overweight
2018-07-16	Eingeleitet	Jefferies	Buy
2018-07-16	Eingeleitet	Leerink Partners	Outperform
2018-07-16	Eingeleitet	RBC Capital Mkts	Outperform

Alle ansehen

Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten

Nov 21, 2025

What drives Xeris Biopharma Holdings Inc 2B30 stock priceDividend Stability Analysis & Stay Safe With Built-In Risk Monitoring - earlytimes.in

Nov 21, 2025

Xeris Biopharma Faces Weak Start with 15% Gap Down Amid Market Concerns - Markets Mojo

Nov 21, 2025

Nov 20, 2025

How higher bond yields impact Xeris Biopharma Holdings Inc. (2B30) stockIndex Update & Accurate Entry/Exit Alerts - newser.com

Nov 20, 2025

Will Xeris Biopharma Holdings Inc. (2B30) stock hit Wall Street targetsPortfolio Value Summary & Low Drawdown Investment Ideas - newser.com

Nov 20, 2025

Nov 19, 2025

Will Xeris Biopharma Holdings Inc. stock deliver long term returns2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - newser.com

Nov 19, 2025

Nov 18, 2025

Detecting support and resistance levels for Xeris Biopharma Holdings Inc.2025 Year in Review & Verified Stock Trade Ideas - newser.com

Nov 18, 2025

Nov 16, 2025

Why Xeris Biopharma Holdings Inc. (2B30) stock appeals to dividend investorsJuly 2025 Rallies & Daily Chart Pattern Signals - newser.com

Nov 16, 2025

Nov 15, 2025

What high frequency data says about Xeris Biopharma Holdings Inc.2025 Support & Resistance & Risk Controlled Swing Alerts - newser.com

Nov 15, 2025

How sentiment analysis helps forecast Xeris Biopharma Holdings Inc.Trade Volume Report & Long-Term Safe Investment Ideas - newser.com

Nov 15, 2025

Nov 13, 2025

Hecht Beth, chief legal officer, sells Xeris Biopharma (XERS) shares for $123k - Investing.com Nigeria

Nov 13, 2025

Nov 12, 2025

Officer Hecht Files To Sell 66,668 Of Xeris Biopharma Holdings Inc [XERS] - TradingView

Nov 12, 2025

Nov 11, 2025

Is Xeris Biopharma Holdings Inc. (2B30) stock supported by strong fundamentalsIPO Watch & Weekly Chart Analysis and Trade Guides - newser.com

Nov 11, 2025

Why Xeris Biopharma Holdings Inc. (2B30) stock is listed among top recommendationsTrade Signal Summary & Risk Adjusted Buy and Sell Alerts - newser.com

Nov 11, 2025

Nov 10, 2025

Is Xeris Biopharma Holdings Inc. (2B30) stock cheap vs fundamentalsJuly 2025 PreEarnings & Stepwise Entry and Exit Trade Signals - newser.com

Nov 10, 2025

Is a relief rally coming for Xeris Biopharma Holdings Inc. holdersStock Surge & Community Consensus Stock Picks - newser.com

Nov 10, 2025

Why Xeris Biopharma Holdings Inc. (2B30) stock could be top winnerWeekly Stock Summary & Daily Stock Trend Reports - newser.com

Nov 10, 2025

Is Xeris Biopharma Holdings Inc. stock entering bullish territoryJuly 2025 Review & Risk Controlled Stock Alerts - newser.com

Nov 10, 2025

Nov 09, 2025

Applying chart zones and confluence areas to Xeris Biopharma Holdings Inc.Oil Prices & Consistent Growth Equity Picks - newser.com

Nov 09, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance

Nov 09, 2025

Nov 08, 2025

Q4 2024 Xeris Biopharma Holdings Inc Earnings Call Transcript - GuruFocus

Nov 08, 2025

Xeris Biopharma (XERS) Turns Profitable and Lifts 2025 Outlook but What Will Sustain Growth? - Sahm

Nov 08, 2025

Nov 07, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2025 Earnings Call Transcript - Insider Monkey

Nov 07, 2025

Xeris raises 2025 revenue guidance to $285M-$290M as RECORLEV revenue more than doubles year-over-year - MSN

Nov 07, 2025

Xeris Biopharma Holdings, Inc. (2B30.F) stock price, news, quote and history - Yahoo Finance Singapore

Nov 07, 2025

Xeris Biopharma Hits Day Low at $7.00 Amid Price Pressure - Markets Mojo

Nov 07, 2025